N@N

BioElectronics Announces Positive Clinical Results - Rapid Recovery Breast Augmentation Study

^{Published on 2008-12-02 10:42:10 - Market Wire}
 

FREDERICK, Md.--([ BUSINESS WIRE ])--BioElectronics Corp. (Pink Sheets:BIEL), the maker of ActiPatch™, the drug-free, anti-inflammatory patch, with an embedded, battery-operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced results from an important clinical study designed to determine the benefits of pulsed electromagnetic therapy using ActiPatch topical patch devices. Significantly positive results were achieved, clearly demonstrating the efficacy and safety of this simple, low-cost method to reduce pain within the first few days after breast augmentation.

The study, full details of which can be viewed at [ www.exploreplasticsurgery.com ], was conducted by prominent plastic surgeon Dr. Barry Eppley from November 2007 to November 2008, tracking forty-eight (48) women undergoing breast augmentation, with active ActiPatch therapy used on one augmented breast and not activated ActiPatch therapy used on the other augmented breast. In total, 73% of women reported less pain and uncomfortability on the breast that received ActiPatch therapy than on the control side. Of the 27% of patients with no decrease in pain on the active side, 21% reported that the pain was similar between sides, with only 6% reporting that the pain was more severe on active side.

Dr. Barry Eppley commented, "In an effort to control pain after breast augmentation, I often employ pulsed electromagnetic therapy using ActiPatch topical patch devices. I designed this study to determine whether there was an actual benefit from using ActiPatch or just a psychotherapeutic effect. The findings of the study are very meaningful. Given its ease of use and lack of any potential for creating any adverse problems, its use as part of a breast augmentation recovery protocol appears to have offer patients some real benefits."

Andrew Wheelan, CEO of BioElectronics, Corp., added, "The release of the study is a highly significant event for our company and we believe it will be very beneficial in receiving additional FDA indications for postsurgical use of our product. Our over-the-counter sales outside of the United States are growing rapidly and we believe this study holds the potential to significantly advance our domestic revenue generation. Over the next few months we plan on releasing additional clinical studies relating to ankle sprains, heel pain, post surgical care for C-sections and additional breast augmentation data. It is clearly an exciting time at BioElectronics, Corp., and we are very positive about both our short-term and long-term future."

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch™. ActiPatch is a drug-free, anti-inflammatory patch with an embedded, battery-operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient-friendly method to reduce soft tissue pain and swelling. For more information, please see [ www.bioelectronics.com ] or [ www.wallstreetreportonline.com ].

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of the company in light of current conditions, expected future developments and other factors it believes to be appropriate.Actual results may differ as a result of factors over which the company has no control.